Advertisement

Heart and Vessels

, Volume 34, Issue 1, pp 95–103 | Cite as

Dilated cardiomyopathy with re-worsening left ventricular ejection fraction

  • Takeru NabetaEmail author
  • Takayuki Inomata
  • Shunsuke Ishii
  • Mayu Yazaki
  • Teppei Fujita
  • Yuichiro Iida
  • Yuki Ikeda
  • Emi Maekawa
  • Takashi Naruke
  • Toshimi Koitabashi
  • Junya Ako
Original Article

Abstract

Re-worsening left ventricular ejection fraction (LVEF) is observed in some patients with dilated cardiomyopathy (DCM) despite initial improvements in LVEF. We analyzed cardiac outcomes and clinical variables associated with this re-worsening LVEF. A total of 180 newly diagnosed DCM patients who received only pharmacotherapy were enrolled. Echocardiography was performed after 6, 12, 24, and 36 months after initiation of pharmacotherapy. Patients were divided into three groups: (1) Improved: (n = 113, 63%), defined as those > 10% increase in LVEF after 12 months and no decrease (> 10%) between 12 and 36 months; (2) Re-worse: (n = 12, 7%), those with > 10% increase in LVEF after 12 months but with decrease (> 10%) between 12 and 36 months; and (3) Not-improved: (n = 55: 30%), those with no increase in LVEF (> 10%) after 12 months. Patients with re-worse group were older (P = 0.04) and had higher brain natriuretic peptide (BNP) levels after 12 months (P = 0.002) than those in the Improved group. Major cardiac events (sudden death, implantation of a ventricular assist device, and death due to heart failure,) were observed in 13 (7%) patients after 36 months of pharmacotherapy. Multivariate analysis revealed that the Re-worse group had a higher risk for cardiac events (hazard ratio 11.7, 95% confidence interval 1.9–90.7, P = 0.01) than the Improved group, but had a similar risk compared with the Not-improved group. Re-worsening LVEF was associated with poor cardiac outcomes in newly diagnosed DCM patients. Age and persistently high-BNP levels after improvement in LVEF were significantly associated with re-worsening LVEF.

Keywords

Heart failure Dilated cardiomyopathy Left ventricular ejection fraction Recovered ejection fraction 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

Supplementary material

380_2018_1214_MOESM1_ESM.docx (22 kb)
Supplementary material 1 (DOCX 22 kb)

References

  1. 1.
    Merlo M, Pyxaras SA, Pinamonti B, Barbati G, Di Lenarda A, Sinagra G (2011) Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment. J Am Coll Cardiol 57:1468–1476CrossRefGoogle Scholar
  2. 2.
    Jefferies JL, Towbin JA (2010) Dilated cardiomyopathy. Lancet 375:752–762CrossRefGoogle Scholar
  3. 3.
    Juilliere Y, Barbier G, Feldmann L, Grentzinger A, Danchin N, Cherrier F (1997) Additional predictive value of both left and right ventricular ejection fractions on long-term survival in idiopathic dilated cardiomyopathy. Eur Heart J 18:276–280CrossRefGoogle Scholar
  4. 4.
    Ikeda Y, Inomata T, Iida Y, Iwamoto-Ishida M, Nabeta T, Ishii S, Sato T, Yanagisawa T, Mizutani T, Naruke T, Koitabashi T, Takeuchi I, Nishii M, Ako J (2016) Time course of left ventricular reverse remodeling in response to pharmacotherapy: clinical implication for heart failure prognosis in patients with idiopathic dilated cardiomyopathy. Heart Vessels 31:545–554CrossRefGoogle Scholar
  5. 5.
    Nabeta T, Inomata T, Iida Y, Ikeda Y, Iwamoto M, Ishii S, Sato T, Watanabe I, Naruke T, Shinagawa H, Koitabashi T, Takeuchi I, Nishii M, Inoue Y, Izumi T (2014) Baseline cardiac magnetic resonance imaging versus baseline endomyocardial biopsy for the prediction of left ventricular reverse remodeling and prognosis in response to therapy in patients with idiopathic dilated cardiomyopathy. Heart Vessels 29:784–792CrossRefGoogle Scholar
  6. 6.
    Nadruz W Jr, West E, Santos M, Skali H, Groarke JD, Forman DE, Shah AM (2016) Heart failure and midrange ejection fraction: implications of recovered ejection fraction for exercise tolerance and outcomes. Circ Heart Fail 9:e002826CrossRefGoogle Scholar
  7. 7.
    Lupon J, Diez-Lopez C, de Antonio M, Domingo M, Zamora E, Moliner P, Gonzalez B, Santesmases J, Troya MI, Bayes-Genis A (2017) Recovered heart failure with reduced ejection fraction and outcomes: a prospective study. Eur J Heart Fail 19(12):1615–1623CrossRefGoogle Scholar
  8. 8.
    Punnoose LR, Givertz MM, Lewis EF, Pratibhu P, Stevenson LW, Desai AS (2011) Heart failure with recovered ejection fraction: a distinct clinical entity. J Card Fail 17:527–532CrossRefGoogle Scholar
  9. 9.
    Basuray A, French B, Ky B, Vorovich E, Olt C, Sweitzer NK, Cappola TP, Fang JC (2014) Heart failure with recovered ejection fraction: clinical description, biomarkers, and outcomes. Circulation 129:2380–2387CrossRefGoogle Scholar
  10. 10.
    Kalogeropoulos AP, Fonarow GC, Georgiopoulou V, Burkman G, Siwamogsatham S, Patel A, Li S, Papadimitriou L, Butler J (2016) Characteristics and outcomes of adult outpatients with heart failure and improved or recovered ejection fraction. JAMA Cardiol 1:510–518CrossRefGoogle Scholar
  11. 11.
    Gupta A, Goyal P, Bahl A (2014) Frequency of recovery and relapse in patients with nonischemic dilated cardiomyopathy on guideline-directed medical therapy. Am J Cardiol 114:883–889CrossRefGoogle Scholar
  12. 12.
    Blechman I, Arad M, Nussbaum T, Goldenberg I, Freimark D (2014) Predictors and outcome of sustained improvement in left ventricular function in dilated cardiomyopathy. Clin Cardiol 37:687–692CrossRefGoogle Scholar
  13. 13.
    de Groote P, Fertin M, Duva Pentiah A, Goeminne C, Lamblin N, Bauters C (2014) Long-term functional and clinical follow-up of patients with heart failure with recovered left ventricular ejection fraction after beta-blocker therapy. Circ Heart Fail 7:434–439CrossRefGoogle Scholar
  14. 14.
    Park JS, Kim JW, Seo KW, Choi BJ, Choi SY, Yoon MH, Hwang GS, Tahk SJ, Shin JH (2014) Recurrence of left ventricular dysfunction in patients with restored idiopathic dilated cardiomyopathy. Clin Cardiol 37:222–226CrossRefGoogle Scholar
  15. 15.
    Moon J, Ko YG, Chung N, Ha JW, Kang SM, Choi EY, Rim SJ (2009) Recovery and recurrence of left ventricular systolic dysfunction in patients with idiopathic dilated cardiomyopathy. Can J Cardiol 25:e147–e150CrossRefGoogle Scholar
  16. 16.
    Dungen HD, Apostolovic S, Inkrot S, Tahirovic E, Krackhardt F, Pavlovic M, Putnikovic B, Lainscak M, Gelbrich G, Edelmann F, Wachter R, Eschenhagen T, Waagstein F, Follath F, Rauchhaus M, Haverkamp W, Osterziel KJ, Dietz R, Cibis-Eld Investigators SMTitCNHF (2008) Bisoprolol vs. carvedilol in elderly patients with heart failure: rationale and design of the CIBIS-ELD trial. Clin Res Cardiol 97:578–586CrossRefGoogle Scholar
  17. 17.
    Ikeda Y, Inomata T, Fujita T, Iida Y, Nabeta T, Ishii S, Maekawa E, Yanagisawa T, Mizutani T, Naruke T, Koitabashi T, Takeuchi I, Ako J (2016) Cardiac fibrosis detected by magnetic resonance imaging on predicting time course diversity of left ventricular reverse remodeling in patients with idiopathic dilated cardiomyopathy. Heart Vessels 31:1817–1825CrossRefGoogle Scholar
  18. 18.
    Leong DP, Chakrabarty A, Shipp N, Molaee P, Madsen PL, Joerg L, Sullivan T, Worthley SG, De Pasquale CG, Sanders P, Selvanayagam JB (2012) Effects of myocardial fibrosis and ventricular dyssynchrony on response to therapy in new-presentation idiopathic dilated cardiomyopathy: insights from cardiovascular magnetic resonance and echocardiography. Eur Heart J 33:640–648CrossRefGoogle Scholar
  19. 19.
    Yoneyama K, Venkatesh BA, Bluemke DA, McClelland RL, Lima JAC (2017) Cardiovascular magnetic resonance in an adult human population: serial observations from the multi-ethnic study of atherosclerosis. J Cardiovasc Magn Reson 19:52CrossRefGoogle Scholar
  20. 20.
    de Lemos JA, McGuire DK, Drazner MH (2003) B-type natriuretic peptide in cardiovascular disease. Lancet 362:316–322CrossRefGoogle Scholar
  21. 21.
    Eschalier R, Fertin M, Fay R, Bauters C, Zannad F, Pinet F, Rossignol P (2013) Extracellular matrix turnover biomarkers predict long-term left ventricular remodeling after myocardial infarction: insights from the REVE-2 study. Circ Heart Fail 6:1199–1205CrossRefGoogle Scholar
  22. 22.
    Eichhorn EJ, Bedotto JB, Malloy CR, Hatfield BA, Deitchman D, Brown M, Willard JE, Grayburn PA (1990) Effect of beta-adrenergic blockade on myocardial function and energetics in congestive heart failure. Improvements in hemodynamic, contractile, and diastolic performance with bucindolol. Circulation 82:473–483CrossRefGoogle Scholar
  23. 23.
    Waagstein F, Caidahl K, Wallentin I, Bergh CH, Hjalmarson A (1989) Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 80:551–563CrossRefGoogle Scholar
  24. 24.
    Metra M, Torp-Pedersen C, Cleland JGF, Di Lenarda A, Komajda M, Remme WJ, Cas LD, Spark P, Swedberg K, Poole-Wilson PA (2007) Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET. Eur J Heart Fail 9:901–909CrossRefGoogle Scholar
  25. 25.
    Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA, Udelson JE (2010) Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction. A meta-analytic approach. J Am Coll Cardiol 56:392–406CrossRefGoogle Scholar

Copyright information

© Springer Japan KK, part of Springer Nature 2018

Authors and Affiliations

  • Takeru Nabeta
    • 1
    Email author
  • Takayuki Inomata
    • 2
  • Shunsuke Ishii
    • 1
  • Mayu Yazaki
    • 1
  • Teppei Fujita
    • 1
  • Yuichiro Iida
    • 1
  • Yuki Ikeda
    • 1
  • Emi Maekawa
    • 1
  • Takashi Naruke
    • 1
  • Toshimi Koitabashi
    • 1
  • Junya Ako
    • 1
  1. 1.Department of Cardiovascular MedicineKitasato University School of MedicineSagamiharaJapan
  2. 2.Department of Cardiovascular MedicineKitasato University School, Kitasato Institute HospitalTokyoJapan

Personalised recommendations